SynthesisJournal of surgical oncology2025
Utility of the Social Vulnerability Index in Addressing Breast Cancer Disparities: A Meta-Analysis.
Synthesis in Journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the utility of the Social Vulnerability Index (SVI) in understanding disparities in breast cancer screening, incidence, and mortality.
backgroundDespite major advances in breast cancer detection and treatment, significant disparities persist-particularly among socioeconomically and geographically vulnerable populations. The SVI, developed by the CDC, is a composite index that captures community-level vulnerability across multiple social domains and may serve as a tool to identify and address inequities in cancer care.
methodsThis systematic review and meta-analysis were conducted in accordance with PRISMA guidelines and registered in PROSPERO (CRD42024616874). PubMed, Scopus, and Embase were searched for studies examining associations between SVI and breast cancer outcomes. Studies were evaluated using the Newcastle-Ottawa Scale or appropriate Cochrane tools. Meta-analyses were performed where applicable.
resultsFifteen studies were included. Seven studies examined screening; a pooled meta-analysis (n = 3) showed reduced screening in high-SVI areas (pooled OR: 0.55, 95% CI: 0.24-1.26; I² = 99%). Four studies reported reduced incidence in high-SVI populations, likely reflecting underdiagnosis. Five studies demonstrated increased mortality in high-SVI populations, with ORs ranging from 1.09 to 2.84. Other studies addressed comorbidities, access to care, and disease subtypes.
conclusionThe SVI is a valuable, multidimensional tool for characterizing and addressing disparities in breast cancer outcomes, with implications for public health interventions and policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.